Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Esophageal Neoplasms 72Esophageal Squamous Cell Carcinoma 41Carcinoma, Non-Small-Cell Lung 32Stomach Neoplasms 31Colorectal Neoplasms 29Ovarian Neoplasms 25Pancreatic Neoplasms 21Adenocarcinoma Of Esophagus 16Breast Neoplasms 15Lung Neoplasms 12Squamous Cell Carcinoma of Head and Neck 10Sarcoma 10Neoplasm Metastasis 10Melanoma 10Liver Neoplasms 10Endometrial Neoplasms 10Colonic Neoplasms 9Neoplasms 8Hepatoblastoma 8Head and Neck Neoplasms 8Cholangiocarcinoma 8Carcinoma, Hepatocellular 8Uterine Cervical Neoplasms 7Urinary Bladder Neoplasms 7Triple Negative Breast Neoplasms 7Carcinoma, Renal Cell 7Anus Neoplasms 7Rectal Neoplasms 6Carcinoma, Squamous Cell 6Testicular Neoplasms 5

Interventions

Chemoradiotherapy 2Radiation 1Paclitaxel 1Granulocyte-Macrophage Colony-Stimulating Factor 1Colony-Stimulating Factors 1Cetuximab 1Carboplatin 1Adjuvants, Immunologic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Resectable Esophageal Cancer × Carboplatin × Gastrointestinal × Clear all
NCT03490292 2024-07-26

Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer

University of Wisconsin, Madison

Phase 1/2 Completed
22 enrolled 17 charts
Gastrointestinal

Resectable Esophageal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡